NCT06787612 2026-04-08
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07109414 2026-03-09
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
Novita Pharmaceuticals, Inc.
Phase 2/3 Active not recruiting
NCT06161025 2026-01-12
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06425302 2026-01-08
GOLSEEK-2
Celgene
Phase 2 Active not recruiting
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT05271318 2025-11-03
PROTA
TILT Biotherapeutics Ltd.
Phase 1/2 Recruiting
NCT03872947 2025-08-03
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1 Active not recruiting
NCT05551507 2025-04-30
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting